Cantor Fitzgerald analyst Kristen Kluska initiated coverage of X4 Pharmaceuticals with an Overweight rating and $3 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on XFOR:
- X4 Pharmaceuticals presents on Mavorixafor at ASH 2022
- X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia
- X4 Pharmaceuticals initiated with an Overweight at Piper Sandler
- X4 Pharmaceuticals 52.3M share Spot Secondary priced at $1.10
- X4 Pharmaceuticals Prices $65.0 Million Public Offering